Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Oncotargets and Therapy
|
September 15, 2018
Profile of abemaciclib and its potential in the treatment of breast cancer
James M Martin, Lori J Goldstein
JAMA Network Open
|
October 13, 2020
In Support of CDK4/6 Inhibitors-A Meta-analysis of Available Randomized Data
James M Martin, Lori J Goldstein
Rhode Island Medical Journal (2013)
|
October 31, 2015
Genomics in acute myeloid leukemia: from identification to personalization
James M Martin, Eric S Winer
Chinese Clinical Oncology
|
December 12, 2018
CD30+ T-cell lymphoproliferative disorders
James M Martin, Hong Wu, Stefan K Barta
BMJ Case Reports
|
January 7, 2018
Rash and subcutaneous fat necrosis after DEB-TACE with doxorubicin
Ahmed Gamal Elsayed, James M Martin, Toni Pacioles
Annual Review of Physiology
|
November 4, 2025
Role of Diverse Smooth Muscle Cell Phenotypic Transitions in Atherosclerosis Development and Late-Stage Pathogenesis
Vlad Serbulea, James M Martin, Gary K Owens
JCO Oncology Practice
|
October 12, 2021
CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer
Priyanka M Reddy, James M Martin, Alberto J Montero
Ground Water
|
March 19, 2013
Controls of wellbore flow regimes on pump effluent composition
James M Martin-Hayden, Mitchell Plummer, Sanford L Britt
The Oncologist
|
May 13, 2022
Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
James M Martin, Elizabeth A Handorf, Alberto J Montero, et al.
Antioxidants (Basel, Switzerland)
|
December 1, 2017
Differential Effects of Superoxide Dismutase Mimetics after Mechanical Overload of Articular Cartilage
Mitchell C Coleman, Marc J Brouillette, Nicholas S Andresen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Oncotargets and Therapy
|
September 15, 2018
Profile of abemaciclib and its potential in the treatment of breast cancer
James M Martin, Lori J Goldstein
JAMA Network Open
|
October 13, 2020
In Support of CDK4/6 Inhibitors-A Meta-analysis of Available Randomized Data
James M Martin, Lori J Goldstein
Rhode Island Medical Journal (2013)
|
October 31, 2015
Genomics in acute myeloid leukemia: from identification to personalization
James M Martin, Eric S Winer
Chinese Clinical Oncology
|
December 12, 2018
CD30+ T-cell lymphoproliferative disorders
James M Martin, Hong Wu, Stefan K Barta
BMJ Case Reports
|
January 7, 2018
Rash and subcutaneous fat necrosis after DEB-TACE with doxorubicin
Ahmed Gamal Elsayed, James M Martin, Toni Pacioles
Annual Review of Physiology
|
November 4, 2025
Role of Diverse Smooth Muscle Cell Phenotypic Transitions in Atherosclerosis Development and Late-Stage Pathogenesis
Vlad Serbulea, James M Martin, Gary K Owens
JCO Oncology Practice
|
October 12, 2021
CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer
Priyanka M Reddy, James M Martin, Alberto J Montero
Ground Water
|
March 19, 2013
Controls of wellbore flow regimes on pump effluent composition
James M Martin-Hayden, Mitchell Plummer, Sanford L Britt
The Oncologist
|
May 13, 2022
Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
James M Martin, Elizabeth A Handorf, Alberto J Montero, et al.
Antioxidants (Basel, Switzerland)
|
December 1, 2017
Differential Effects of Superoxide Dismutase Mimetics after Mechanical Overload of Articular Cartilage
Mitchell C Coleman, Marc J Brouillette, Nicholas S Andresen, et al.
Page
of 2